Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Luminal (phenobarbital) [package insert]. Eatontown, NJ: West-Ward Pharmaceuticals; 2017.

Horn

Hansen

Chan

LN.

Proposal for a new tool to evaluate drug interaction studies. Ann Pharmacother. 2007;41:674-680. doi:10.1345/aph.1H423

Eliquis (apixaban) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2017.

Døssing

Pilsgaard

Rasmussen

Poulsen

HE.

Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol. 1983;25:215-222.

Fukunaga

Saito

Matsuo

et al . Long-lasting enhancement of CYP activity after discontinuation of repeated administration of phenobarbital in dogs. Res Vet Sci. 2009;87:455-457. doi:10.1016/j.rvsc.2009.03.018

Wiggins

Northup

Johnson

Senfield

Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin. Pharmacotherapy. 2016;36:e5-e7. doi:10.1002/pharm.1698

Chin

PKL

Wright

DFB

Zhang

et al . Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drug R D. 2004;14:113-123. doi:10.1007/s40268-014-0045-9

Management of Phenobarbital and Apixaban Interaction in Recurrent Cardioembolic Stroke

Abstract

Get full access to this article

References